Tradestie Institutional Equity Comparison Engine
NVS vs GSK โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
NVS Overall Edge
NVS Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Novartis AG (NVS) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while GSK counters with relative strength in Valuation. Fundamentally, NVS trades at 16.2x Forward P/E with 34.0% operating margin (+4.7% YoY revenue) versus GSK at 10.2x Forward P/E and 30.5% operating margin (+4.0% YoY). In options structure, NVS sits in UNCLASSIFIED (6th %ile IV; Dealer Gamma Walls on Pro) against GSK sits in UNCLASSIFIED (39th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
GSK
NVS 16.2x vs GSK 10.2x Fwd P/E
Growth & Margin Winner
NVS
Op Margin 34.0% vs 30.5% ยท YoY +4.7% vs +4.0%
Momentum & Technical Winner
NVS
1Y +22.5% vs +5.5% ยท 52W Pos 81% vs 31%
Options & Structure Winner
NVS
UNCLASSIFIED (6th %ile IV) vs UNCLASSIFIED (39th %ile IV)
NVS
NYSE
Novartis AG
Pharmaceutical Preparations
$161.59
+0.68% 1D
Market Cap
$302.9B
1M Return
+7.28%
1Y Return
+22.5%
Forward P/E
16.2x
Unified AI Score
41.5 / 100
SELL
Tech 29.0
Fund 38.0
Flow 50.0
Mom 21.1
GSK
NYSE
GSK plc American Depositary Shares (Each representing two Ordinary Shares)
Pharmaceutical Preparations
$50.77
+0.63% 1D
Market Cap
$101.5B
1M Return
+2.54%
1Y Return
+5.46%
Forward P/E
10.2x
Unified AI Score
42.7 / 100
HOLD
Tech 41.0
Fund 38.0
Flow 50.0
Mom 11.5
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
NVS +22.5%
GSK +5.46%
Spread: +17.04 pp (NVS Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
NVS TTM Op. Margin: 34.0%
GSK TTM Op. Margin: 30.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NVS vs GSK. Trailing 12-month operating profitability (NVS 34.0% vs GSK 30.5%) and valuation multiples (NVS 16.2x vs GSK 10.2x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | NVS | GSK | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $302.9B | $101.5B | Larger Scale | NVS |
| Trailing P/E Ratio Valuation | 30.6x | 17.6x | Lower Multiple | GSK |
| Forward P/E Ratio Valuation | 16.2x | 10.2x | Lower Multiple | GSK |
| Revenue Growth (YoY) Growth | +4.7% | +4.0% | Higher Growth | NVS |
| Operating Margin (TTM) Profitability | 34.0% | 30.5% | Higher Margin | NVS |
| Net Profit Margin Profitability | 17.5% | 13.0% | Higher Margin | NVS |
| Return on Equity (ROE) Capital Efficiency | 24.3% | 28.3% | Higher ROE | GSK |
| 52-Week Range Position Momentum | 81% ($123โ$170) | 31% ($46โ$62) | Stronger Trend | NVS |
| Beta / 30D Volatility Risk Regime | 0.31ฮฒ ยท 27% Vol | 0.27ฮฒ ยท 30% Vol | Lower Realized Risk | NVS |
| Unified Institutional Score Composite Signal | 41.5 / 100 (SELL) | 42.7 / 100 (HOLD) | Higher Composite | GSK |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full NVS vs GSK Buy Guide
NVS
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
6th %ile
IV Regime
Compressed (<25th %ile)
GSK
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
39th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither NVS nor GSK registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.